DMRADamora Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$211M
- 848% YoY
- Market cap
- $1.3B
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- 0.1
- mentions per 10K words
Takeover score 2 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$1M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo100% lowest supportAny vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AIYes0.1 per 10K words · 9th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$1.3B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$222K netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$52M | −$61M | −$40M | −$22M | −$211M | 847% |
| Net income | −$52M | −$62M | −$38M | −$21M | −$210M | 879% |
| Operating cash flow | −$52M | −$43M | −$37M | −$19M | −$7M | 64% |
| Capex | $223K | $196K | — | — | — | |
| Stock-based comp | $4M | $6M | $5M | $3M | $998K | 69% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Feb 11, 2026 | Fairmount Funds Management LLC | SCHEDULE 13D/A | 20.0% | Passive |
| Nov 17, 2025 | Fairmount Funds Management LLC | SCHEDULE 13D | 20.0% | Passive |
| Oct 9, 2025 | Novo Holdings A/S | SCHEDULE 13D/A | 0.0% | Passive |
| Sep 25, 2025 | Novo Holdings A/S | SCHEDULE 13D/A | 6.5% | Passive |
| Jan 16, 2025 | Novo Holdings A/S | SCHEDULE 13D/A | 7.6% | Passive |
| Jun 24, 2024 | Novo Holdings A/S | SC 13D/A | 9.2% | Passive |
| Sep 18, 2023 | ORBIMED ADVISORS LLC | SC 13D/A | 2.8% | Passive |
| Sep 5, 2023 | ORBIMED ADVISORS LLC | SC 13D/A | 4.2% | Passive |
| Aug 17, 2023 | ORBIMED ADVISORS LLC | SC 13D/A | 5.9% | Passive |
| Aug 2, 2023 | ORBIMED ADVISORS LLC | SC 13D/A | 8.3% | Passive |
Insider trading
- Open-market buys, 12 mo
- $253K · 1
- Open-market sells, 12 mo
- $31K · 4
- Net
- $222K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $1M | $2M | 128 | — |
| FY2024 | $1M | $1M | 26 | — |